Dermatomyositis and Myelodysplastic Syndrome with Myelofibrosis Responding to Methotrexate Therapy

American Journal of Hematology

Volumn 74, Issue 3, 2003, Pages 175-178

  Tsuji, Goh ^a   Maekawa, Soichiro ^a   Saigo, Katsuyasu ^b   Nobuhara, Yumiko ^a   Nakamura, Tomoko ^a   Kawano, Seiji ^a   Koshiba, Masahiro ^a   Asahara, Shunichiro ^c   Chinzei, Tadanobu ^c   Kumagai, Shunichi ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c Kakogawa Municipal Hospital   (Japan)

Author keywords

Dermatomyositis; Methotrexate; Myelodysplastic syndrome; Myelofibrosis

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW CELL; CASE REPORT; CELL MATURATION; CELL STRUCTURE; DERMATOMYOSITIS; DISEASE COURSE; ERYTHEMA; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL;

BLOOD CELLS; BONE MARROW CELLS; DERMATOMYOSITIS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; TREATMENT OUTCOME;

EID: 0242361658     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10430     Document Type: Article

References (19)

1. Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-367.
2. Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15:597-601.
3. Sugawara T, Endo K, Shishido T, et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 1992;41:304-305.
4. Ferrara F, Copia C, Annunziata M, et al. Complete remission of refractory anemia following a single high dose of cyclophosphamide. Ann Hematol 1999;78:87-88.
5. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
6. Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18:721-727.
7. Enright H, Miller W. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997;24:483-489.
8. Okamoto T, Okada M, Mori A, et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66:345-351.
9. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993;100:534-540.
10. Bain B, Vardiman JW, Imbert M, Pierre P. Myelodysplastic/myeloproliferative disease, unclassifiable. World Health Organization Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. 58-59 p.
11. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 1983;62:353-371.
12. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990;75:4-9.
13. Mhawech P, Saleem A. Myelodysplastic syndrome: review of the cytogenetic and molecular data. Crit Rev Oncol Hematol 2001;40:229-238.
14. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;113:763-771.
15. Bass RD, Pullarkat V, Feinstein DI, Kaul A, Winberg CD, Brynes RK. Pathology of autoimmune myelofibrosis. A report of three cases and a review oh the literature. Am J Clin Pathol 2001;116:211-216.
16. Maeda Y, Arakawa K, Araki E, et al. Polymyositis and cutaneous vasculitis in a patient with myelodysplastic syndrome [in Japanese with English abstract]. Rinsho Shinkeigaku 1999;39:636-642.
17. Rosental NS, Farhi DC. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single agent chemotherapy. Am J Clin Pathol 1996;106:676-679.
18. Motomura S, Motoji T, Okutomi K, Toshio N, Takeshi K, Mizoguchi H. Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow. Am J Hematol 2001;66:80-84.
19. Ohyashiki K, Sasano I, Ohyashiki JH, et al. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 1991;68:178-183.